Halle (Saale)

News and Video Search Results

News coverage

Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates

GlobeNewswire 24 Apr 2024

*Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates..

Why We Need Alternative Media – OpEd
Eurasia Review 17 Apr 2024
Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024
GlobeNewswire 16 Apr 2024
Study: Stainless steel circular economy significantly reduces the risk of climate change in ThailandPR 27
Media OutReach 27 Mar 2024
Study: Stainless steel circular economy significantly reduces the risk of climate change in Thailand
Pressat 27 Mar 2024

0 shares 2 views

You might like

Halle (Saale) media coverage

Vivoryon Therapeutics N.V. Announces Changes to Board Composition

GlobeNewswire 15 Mar 2024

*Vivoryon Therapeutics N.V. Announces Changes to Board Composition*

*
*

*Halle (Saale) / Munich,..

Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease
GlobeNewswire 04 Mar 2024
Amid farmers’ protests and disruptions, German bishop calls for dialogue
CNA 08 Jan 2024
Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024
GlobeNewswire 08 Jan 2024
Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
GlobeNewswire 06 Dec 2023

Advertisement

More coverage

Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023

GlobeNewswire 28 Nov 2023

*Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6,..

Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference
GlobeNewswire 07 Nov 2023
Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision
GlobeNewswire 26 Oct 2023
Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer’s Disease to Proceed at Highest Investigated Dose
GlobeNewswire 23 Oct 2023
Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion Leaders
GlobeNewswire 17 Oct 2023